Value Dossier Icon

About Christian Schneider

This author has not yet filled in any details.
So far Christian Schneider has created 35 blog entries.

Our new AMNOG Negotiation Guide is online now!

With the SHI Financial Stabilisation Act (GKV-FinStG), the framework conditions for price negotiations for medicinal products in Germany have been made more complex and have been systematically tightened by the legislator to the disadvantage of the pharmaceutical industry. On the one hand the extend of the additional benefit and on the other hand the

Non-randomised studies and non-adjusted indirect comparisons

Overview of our services in the field of non-randomised studies and indirect comparisons Strategic consulting Systematic research Study design consulting Statistical consulting Non-randomised studies and non-adjusted indirect comparisons in benefit assessments Benefit assessments, at EU level as well as full assessments in Germany, are used to compare the efficacy and safety of a health

Introduction of confidential reimbursement prices sets the wrong incentives!

We are pleased to inform you that our analysis of confidential reimbursement prices in Germany has been published in the journal "Market Access & Health Policy": Schnorpfeil W, Kiehlmeier S. Einführung vertraulicher Erstattungsbeträge setzt falsche Anreize. Market Access & Health Policy. 2024; 2: 28–31. German article English summary

2024-04-10T10:00:43+02:0010. April 2024|Reimbursement|0 Comments

Transition to EU HTA – Consequences of an existence of national and EU HTA in parallel

Overview of our services Strategic advice   Regulation (EU) 2021/2282 Article 7 (1) of Regulation (EU) 2021/2282 specifies when a health technology must undergo a Joint Clinical Assessment (JCA). Paragraph 1a stipulates that the time of initial market authorization application (MAA) is decisive. A JCA of the new health technology only needs to be

2024-04-19T12:58:28+02:0019. February 2024|European HTA|0 Comments

Confidentiality of the reimbursement amount has its price!

As part of the dialogue with the pharmaceutical industry, the German government has promised to introduce the option of a confidential reimbursement amount. The aim is to support pharmaceutical companies whose products are subject to a considerable price decrease after undergoing an AMNOG benefit assessment by offering the option to keep the new price confidential.

Price negotiations with the SHI under consideration of the legal changes

SAVE THE DATE: 16.01.2024 From 10:00 am to 11:30 am Speakers: Dr. Willi Schnorpfeil, Dr. Angela Lammert We are offering a webinar on the topic of "Price negotiations with the SHI under consideration of the legal changes". The webinar is aimed at managing directors and employees of pharmaceutical companies who are involved in pricing issues

2024-02-02T09:57:32+01:0014. December 2023|Reimbursement|0 Comments

Our HospitalAnalyzer is now available!

Based on the quality assurance data of the G-BA, we provide analyses on German hospitals for your market planning. For example: What are the top hospitals for AML in remission (C92.01 according to ICD-10)? Top 5 Hospitals: University Medical Center of Johannes Gutenberg University Mainz University Hospital Giessen and Marburg, Giessen site Municipal Hospital Braunschweig

2023-01-11T13:03:43+01:0011. January 2023|Allgemein|0 Comments

Further specifications on the GKV-FinStG law

In their 2nd and 3rd reading, the German Parliament has decided further specifications of the new law on the financial stabilisation of the statutory health insurances (GKV-FinStG). As already outlined in the draft of the law, the outcome of the AMNOG benefit assessment will further gain importance for the subsequent price negotiations. In case the

Pharmabarometer Update

Have a look at our latest update of German price negotiations for drugs that went through the AMNOG benefit assessment. The mean price decrease after negotiations was 28 % for all analysed products, 23 % for orphan drugs and 30 % for non-orphan drugs. If you have any further questions or suggestions, please feel free

2022-08-23T09:27:36+02:0023. August 2022|Reimbursement|0 Comments

GKV-FinStG cabinet decision: Power shift in favor of the statutory health insurance companies expected

The German cabinet, the coalition group of ministers,  has decided to introduce the draft bill on the financial stabilization of the statutory health insurance (GKV-FinStG) into the parliamentary process [GKV-Finanzstabilisierungsgesetz - Bundesgesundheitsministerium]. The subjects of the draft bill are amendments to the Social Code Book V, in particular sections § 35a and § 130b, which

Go to Top